Kestra Medical Technologies announced full exercise of IPO over-allotment, raising approximately $232 million from 13.6 million shares sold.
Quiver AI Summary
Kestra Medical Technologies, Ltd. has announced that underwriters for its initial public offering fully exercised their over-allotment option, purchasing 1,782,352 shares at $17.00 each. This brings the total number of shares sold in the IPO to 13,664,704, generating approximately $232 million in gross proceeds before expenses. The sale closed today, and BofA Securities, Goldman Sachs & Co. LLC, and Piper Sandler served as lead bookrunners. The registration statement for the offering has become effective, and the prospectus is available through the mentioned financial institutions. Kestra aims to improve patient outcomes in cardiovascular disease through innovative wearable medical devices and digital healthcare solutions.
Potential Positives
- Kestra successfully raised approximately $232 million in gross proceeds from its initial public offering, indicating strong market interest and financial backing.
- The exercise of the over-allotment option indicates confidence from underwriters in the demand for Kestra's shares, reflecting positively on the company's market position.
- The offering involved reputable financial institutions as underwriters, which can enhance Kestra's credibility and visibility in the investment community.
- The capital raised will likely support Kestra's mission of transforming patient outcomes in cardiovascular disease, positioning the company for future growth and innovation in its sector.
Potential Negatives
- None
FAQ
What was the total number of shares sold in Kestra's IPO?
The total number of shares sold by Kestra in the initial public offering was 13,664,704.
How much gross proceeds did Kestra raise from the IPO?
Kestra raised approximately $232 million in gross proceeds from the initial public offering.
Who acted as the lead bookrunners for Kestra's IPO?
BofA Securities, Goldman Sachs & Co. LLC, and Piper Sandler acted as lead bookrunners for the offering.
When did the registration statement for Kestra's common shares become effective?
The registration statement for Kestra's common shares became effective on March 5, 2025.
How can potential investors obtain a prospectus for Kestra's offering?
Copies of the prospectus can be obtained from BofA Securities, Goldman Sachs & Co. LLC, or Piper Sandler via email or phone.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
Full Release
KIRKLAND, Wash., March 14, 2025 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (“Kestra”), a wearable medical device and digital healthcare company, announced today that the underwriters of Kestra’s initial public offering exercised in full their previously disclosed over-allotment option and have purchased 1,782,352 shares of common stock at a public offering price of $17.00 per share. After giving effect to the sale of over-allotment option, the total number of shares sold by Kestra in the initial public offering was 13,664,704 and the total gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Kestra, were approximately $232 million. The issuance and sale of the over-allotment option closed today.
BofA Securities, Goldman Sachs & Co. LLC and Piper Sandler acted as lead bookrunners for the offering. Wells Fargo Securities and Stifel acted as bookrunners and Wolfe | Nomura Alliance acted as co-manager for the offering.
A registration statement relating to the common shares sold in this offering was filed with the Securities and Exchange Commission and became effective on March 5, 2025. The offering was made only by means of a prospectus. Copies of the prospectus may be obtained from BofA Securities, Attention: Prospectus Department, NC1-022-02-25, 201 North Tryon Street, Charlotte, NC 28255-0001, or by email at dg.prospectus_requests@bofa.com; from Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, by facsimile at 212-902-9316, by email at Prospectus-ny@ny.email.gs.com, or by calling 1-866-471-2526; or Piper Sandler, by email at prospectus@psc.com, or by calling (800) 747-3924.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Kestra
Kestra Medical Technologies, Ltd. is a commercial-stage wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected.
Disclaimer
“Wolfe | Nomura Alliance” is the marketing name used by Wolfe Research Securities and Nomura Securities International, Inc. in connection with certain equity capital markets activities conducted jointly by the firms. Both Nomura and Wolfe Research Securities are serving as underwriters in the offering described herein. In addition, Wolfe Research Securities may provide sales support services, investor feedback, investor education, and/or other independent equity research services in connection with the offering.
This article was originally published on Quiver News, read the full story.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
